CoChat

Modeling Targeted Inhibition of MEK and PI3 Kinase in Human Pancreatic Cancer

Junttila, Melissa R., Devasthali, Vidusha, Cheng, Jason H., Castillo, Joseph, Metcalfe, Ciara, Clermont, Anne C., Otter, Douglas Den, Chan, Emily, Bou-Reslan, Hani, Cao, Tim, Forrest, William, Nannini, Michelle A., French, Dorothy, Carano, Richard, Merchant, Mark, Hoeflich, Klaus P., Singh, Mallika · 2015 · Molecular Cancer Therapeutics
Cited by 62

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Activating mutations in the KRAS oncogene occur in approximately 90% of pancreatic cancers, resulting in aberrant activation of the MAPK and the PI3K pathways, driving malignant progression. Significant efforts to develop targeted inhibitors of nodes within these pathways are underway and several are currently in clinical trials for patients with KRAS-mutant tumors, including patients with pancreatic cancer. To model MEK and PI3K inhibition in late-stage pancreatic cancer, we conducted preclinical trials with a mutant Kras-driven genetically engineered mouse model that faithfully recapitulates human pancreatic ductal adenocarcinoma development. Treatment of advanced disease with either a MEK (GDC-0973) or PI3K inhibitor (GDC-0941) alone showed modest tumor growth inhibition and did not significantly enhance overall survival. However, combination of the two agents resulted in a significant survival advantage as compared with control tumor-bearing mice. To model the clinical scenario, we also evaluated the combination of these targeted agents with gemcitabine, the current standard-of-care chemotherapy for pancreatic cancer. The addition of MEK or PI3K inhibition to gemcitabine, or the triple combination regimen, incrementally enhanced overall survival as compared with gemcitabine alone. These results are reminiscent of the survival advantage conferred in this model and in patients by the combination of gemcitabine and erlotinib, an approved therapeutic regimen for advanced nonresectable pancreatic cancer. Taken together, these data indicate that inhibition of MEK and PI3K alone or in combination with chemotherapy do not confer a dramatic improvement as compared with currently available therapies for patients with pancreatic cancer. Mol Cancer Ther; 14(1); 40–47. ©2014 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-14-0030

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 62

Metadata

Authors
Junttila, M. R., Devasthali, V., Cheng, J. H., Castillo, J., Metcalfe, C., Clermont, A. C., Otter, D. D., Chan, E., Bou-Reslan, H., Cao, T., Forrest, W., Nannini, M. A., French, D., Carano, R., Merchant, M., Hoeflich, K. P., & Singh, M.
Venue
Molecular Cancer Therapeutics
Published
2015-01-01
Volume
14
Issue
1
Pages
40-47
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2138277627
Cited by
62
References
13
FWCI
3.45
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Modeling Targeted Inhibition of MEK and PI3 Kinase in Human Pancreatic Cancer. https://app.cochat.ai/papers/10.1158/1535-7163.mct-14-0030
The paper
Junttila, M. R., Devasthali, V., Cheng, J. H., Castillo, J., Metcalfe, C., Clermont, A. C., Otter, D. D., Chan, E., Bou-Reslan, H., Cao, T., Forrest, W., Nannini, M. A., French, D., Carano, R., Merchant, M., Hoeflich, K. P., & Singh, M. (2015). Modeling Targeted Inhibition of MEK and PI3 Kinase in Human Pancreatic Cancer. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-14-0030

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.